Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 12/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441294 | 0.85 | ATR (0.51) | ATRCYP3A4ACVR1 | |
| SCHEMBL439511 | 0.78 | ACVR1 (0.52) | ATRHCRTR1HCRTR2PIN1ABL1 | |
| SCHEMBL12024786 | 0.78 | HCRTR1 (0.54) | HCRTR1HCRTR2 | |
| SCHEMBL10134750 | 0.76 | HCRTR1 (0.50) | HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL13443055 | 0.76 | HCRTR1 (0.57) | HCRTR1HCRTR2 | |
| SCHEMBL441224 | 0.75 | ATR (0.48) | ATRCYP3A4KMT2A | |
| SCHEMBL25735645 | 0.74 | CYP19A1 (0.56) | ATRCYP3A4ABL1 | |
| SCHEMBL30785740 | 0.74 | CYP19A1 (0.56) | ATRCYP3A4ABL1 | |
| SCHEMBL12359372 | 0.73 | HTT (0.53) | CYP3A4HCRTR1HCRTR2KMT2A | |
| SCHEMBL13498677 | 0.72 | HCRTR2 (0.51) | CYP3A4HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | ATR 3803/4885CYP3A4 3617/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.